Bioventus Inc. (NYSE:BVS) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in Bioventus Inc. (NYSE:BVS) by 11.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 435,344 shares of the company’s stock after purchasing an additional 45,182 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Bioventus were worth $4,571,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Principal Financial Group Inc. purchased a new position in Bioventus in the 3rd quarter valued at approximately $210,000. Quest Partners LLC purchased a new position in Bioventus in the third quarter valued at $51,000. Intech Investment Management LLC acquired a new position in Bioventus during the 3rd quarter worth $167,000. FMR LLC grew its stake in Bioventus by 21,256.6% during the 3rd quarter. FMR LLC now owns 166,795 shares of the company’s stock worth $1,993,000 after purchasing an additional 166,014 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in Bioventus by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 22,981 shares of the company’s stock worth $275,000 after purchasing an additional 12,949 shares during the period. 62.94% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BVS has been the subject of a number of analyst reports. Canaccord Genuity Group reissued a “buy” rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th. JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Bioventus Stock Down 3.0 %

Shares of NYSE BVS opened at $9.43 on Wednesday. The business has a 50-day moving average of $10.12 and a two-hundred day moving average of $11.01. The company has a market capitalization of $772.73 million, a price-to-earnings ratio of -15.46 and a beta of 0.86. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99.

Insider Transactions at Bioventus

In related news, SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the completion of the sale, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at $1,204,233.82. The trade was a 3.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert E. Claypoole sold 28,786 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $261,952.60. Following the transaction, the chief executive officer now directly owns 64,964 shares in the company, valued at approximately $591,172.40. The trade was a 30.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,161 shares of company stock valued at $436,364. Corporate insiders own 32.90% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.